Immunex Message Board - Msg: 14286567

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Yang who started this subject	8/28/2000 12:48:55 PM
From: manfredhasler	of 656

Re: XOMA a competitor in Psoriasis treatment Monday, August 28, 2000 US Bancorp bullish on XOMA --12:23 pm - By Michael Baron U.S. Bancorp Piper Jaffray raised its price target for XOMA Ltd. (XOMA: news, msgs) Monday, citing increased optimism about the company's anti-CD11a treatment for psoriasis. U.S. Bancorp analyst Mark Augustine, who rates XOMA a "strong buy", also raised his 52-week target on the stock to $18. Xoma, which is jointly developing anti-CD11a with Genentech (DNA: news, msgs), is up 2 1/8, or 27.2 percent, to 9 15/16. U.S. Bancorp initiated coverage of the Berkley, Calif., developer of products for immunological disorders with a $14 price target on July 11.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next